Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sarepta Therapeutics Inc SRPT

Healthcare Biotechnology
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy... see more

Recent & Breaking News (NDAQ:SRPT)

Hot Stocks Radar: Sarepta Therapeutics, Synta Pharmaceuticals, Lululemon Athletica, Inc, Canadian Solar Inc

Accesswire December 12, 2013

Five Star Equities Issues New Research Reports on ECTE, EXTR, HRL and SRPT

Accesswire November 27, 2013

Sarepta Therapeutics to Present Company Overview at Upcoming Conferences

Marketwired November 19, 2013

INVESTOR ALERT: Federman & Sherwood Investigates Sarepta Therapeutics, Inc. for Possible Securities Laws Violations

Business Wire November 13, 2013

Levi & Korsinsky, LLP Launches Investigation of SAREPTA THERAPEUTICS, INC. for Possible Violations of Federal Securities Laws

PR Newswire November 13, 2013

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

PR Newswire November 13, 2013

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sarepta Therapeutics, Inc.

PR Newswire November 12, 2013

SRPT, HOLX, QUIK and VNDA added to NASDAQ Active Stock Watch List at GSR

Accesswire November 12, 2013

Sarepta Therapeutics Announces Third Quarter 2013 Financial Results and Recent Corporate Developments

Marketwired November 12, 2013

Sarepta Therapeutics Announces FDA Considers NDA Filing for Eteplirsen Premature in Light of Recent Competitive Drug Failure and Recent DMD Natural History Data

Marketwired November 12, 2013

Five Star Equities Issues New Research Reports on RPTP, SRPT, SUPN and VRX

Accesswire November 1, 2013

Sarepta Therapeutics to Announce Third Quarter 2013 Financial Results and Corporate Update on November 12, 2013

Marketwired October 24, 2013

Parent Project Muscular Dystrophy and Sarepta Therapeutics Join Forces on Genetic Testing Program for Patients With Duchenne Muscular Dystrophy

Marketwired October 17, 2013

Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on October 17, 2013

Marketwired October 10, 2013

Cellular Biomedicine Has Multiple Near-Term Catalysts

Accesswire October 3, 2013

Sarepta Therapeutics Introduces Online Resource Center on Exon Skipping for the Duchenne Muscular Dystrophy Community

Marketwired October 2, 2013

Sarepta Therapeutics Announces Eteplirsen Demonstrates Continued Stability on Walking Test Through 96 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy

Marketwired September 26, 2013

Five Star Equities Issues New Research Reports on CYCC, RNA, RVP and SRPT

Accesswire September 23, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on BIIB, CYTK, ISIS and SRPT

Accesswire September 6, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on MTX, PSMI, SCSS and SRPT

Accesswire August 28, 2013